We previously demonstrated that the human nicotinamide N-methytransferase (NNMT) gene was highly expressed in many papillary thyroid cancers and cell lines. The expression in other papillary and follicular cancers or cell lines and normal thyroid cells was low or undetectable. To gain an understanding of the molecular mechanism of this cellspecific expression, the NNMT promoter was cloned and studied by luciferase reporter gene assay. The promoter construct was expressed highly in papillary cancer cell lines, including those with higher (e.g. BHP 2-7) and lower (e.g. BHP 14-9) NNMT gene expression, and expressed weakly in follicular thyroid cancer cell lines. Further study with 5-deletion promoter construct suggested that the NNMT promoter was regulated differently in BHP 2-7 and BHP 14-9 cells. In BHP 2-7 cells, promoter activity was dependent on an upstream sequence. In BHP 14-9 cells, sequence in the basal promoter region contributed notably to the overall promoter activity. RT-PCR or Western blot analysis indicated that hepatocyte nuclear factor-1␤ (HNF- 
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NNMT is a methytransferase structurally and functionally related to thioether S-methytransferase and phenylethanolamine N-methytransferase (3) . NNMT has broad substrate specificity. It catalyzes the Nmethylation of nicotinamide, pyridines, and other structural analogs and is involved in the biotransformation of many drugs and xenobiotic compounds (4) . Human liver displays a significant variation in NNMT activity among individuals. This variation may contribute to the difference in metabolism, therapeutic effect, and toxicity of drugs (3) . Nicotinamide, a favorite substrate of NNMT, is used for the synthesis of nicotinamide adenine dinucleotide (NAD ϩ ) via a salvage pathway and is an inhibitor of the DNA repair enzyme poly (ADP-ribose) polymerase (5) and the NAD ϩ -dependent histone/protein deacetylases, such as silent information regulator 2 (Sir2) (yeast) and sirtuin 1 (human) (6) (7) (8) . Sirtuin 1 deacetylates p53 tumor suppressor and inhibits the p53-dependent apoptotic pathway (9, 10) . In yeast, enzymes involved in a nuclear NAD ϩ salvage pathway have been reported to have effects on Sir2-dependent gene silencing. Inactivation of nicotinate phosphoribosyltransferase by gene mutation caused defects in Sir2-dependent gene silencing (11) . Depletion of nicotinamide by increased expression of nicotinate phosphoribosyltransferase gene or nicotinamidase gene increased the Sir2-dependent silencing (12) (13) (14) , whereas exogenous nicotinamide decreased Sir2-dependent gene silencing (6) . As NNMT irreversibly converts nicotinamide into N (1)-methylnicotinamide, its potential role in the regulation of the NAD ϩ -dependent histone/protein deacetylase activity is implied. The effect of NNMT on Sir2 activity by modulating nicotinamide level was investigated in yeast. It was shown that manipulating expression of human NNMT or its yeast homolog (YLR285W) had effects similar to those from manipulating nicotinamidase on Sir2-dependent gene silencing and yeast lifespan (14) . Recently, NNMT was suggested to be involved in the pathogenesis of Parkinson's disease (15) (16) (17) . It is believed that overexpression of NNMT in parkinsonian cerebellum may increase the level of toxic pyridinium ions and decrease NAD ϩ level, causing a decrease in the viability of dopaminergic neurons over a lifetime (17) .
NNMT is highly expressed in the liver and weakly expressed in heart, placenta, lung, skeletal muscle, and kidney (3) . In addition to papillary thyroid cancer cells, abnormal expression of NNMT has been reported in many situations (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) . The mechanisms for the abnormal expression of NNMT in all situations are unknown. In this work, we studied the molecular mechanism leading to overexpression of NNMT in papillary thyroid cancer cell lines. We found that hepatocyte nuclear factor-1␤ (HNF-1␤) is expressed in many papillary cancer cell lines and activates NNMT promoter. HNF-1␤ was initially identified as a liverspecific transcription factor (26) . It binds to DNA either as a homodimer (HNF-1␤/␤) or heterodimer (HNF-1␣/␤) with HNF-1␣, a functionally and structurally related protein, to regulate target gene expression (26) (27) (28) (29) (30) (31) (32) (33) (34) . HNF-1␤ and HNF-1␣ are highly homologous in three regions, the dimerization domain, B domain, and homeodomain, but differ in the transcription activation domain. HNF-1␤ expression has been detected in a variety of tissues, such as liver, kidney, intestine, stomach, and pancreas (35) (36) (37) . Mutations in the HNF-1␤ gene cause maturity-onset diabetes of the young type 5 (38, 39) . In this study, we showed that HNF-1␤ is expressed in many papillary thyroid cancer cell lines and is involved in the activation of NNMT transcription.
RESULTS

Cloning and Expression of NNMT Promoter in Human Papillary Thyroid Cancer Cells
NNMT promoter sequence from Ϫ2607 to ϩ 1 relative to the translation initiation codon was amplified from genomic DNA isolated from papillary thyroid cancer cell BHP 18-21, a line that expresses endogenous NNMT at a high level (2) . The PCR fragment was digested with restriction enzymes, KpnI and MluI, and cloned into corresponding sites in the luciferase reporter gene vector, pGL3-basic. The sequence of the DNA clone was confirmed to be identical to the NNMT genomic sequences in the GenBank database.
To determine whether the cloned NNMT sequence carries essential elements for expression in papillary thyroid cancer cells, the resulting NNMT luciferase reporter plasmid pKM (Fig. 1) Fig. 1 show that the reporter gene construct was expressed well in all papillary cancer cell lines. The luciferase activity of BHP 2-7 was more than 500 times that of pGL3-basic vector. In contrast, all the follicular cancer cell lines had very low NNMT promoter activity. This result is consistent with our previous study (2) . In addition, NNMT promoter activity in the Hep G2 liver cancer cells was also significantly lower than that in the papillary cancer cells. The cloned NNMT promoter sequence seems to contain important regulatory elements for efficient expression in the papillary thyroid cancer cells.
We previously reported that NNMT mRNA levels in BHP 2-7 and BHP 18-21 cells were significantly higher than that in BHP 5-16, BHP 14-9, BHP 15-3, and NPA 87 cells (2) . This difference is not reflected by promoter activity assay with the reporter construct carrying NNMT DNA sequence from Ϫ2607 to ϩ1 because this construct expressed well in the two subsets of papillary cancer cells (Fig. 1) . To investigate whether NNMT promoter is regulated by a similar mechanism in the two subsets of papillary cancer cell lines, a 5Ј-deletion construct (pKM⌬1) was created by deletion of NNMT upstream DNA sequence between Ϫ2706 and Ϫ343 from pKM ( Fig. 1) . NNMT promoter activity of pKM⌬1 was measured in two representative papillary cancer cell lines, BHP 2-7 and BHP 14-9, as well as in follicular cell line WRO 82-1 and liver cancer cell line Hep G2. The upstream sequence deletion decreased promoter activity dramatically in BHP 2-7 cells and moderately in other cell lines. The deletion decreased promoter activity about 15-fold in BHP 2-7, less than 3-fold in BHP 14-9, and about 2-fold in WRO 82-1 and Hep G2 cells (Fig. 1) . These results suggested that the sequence between Ϫ2706 and Ϫ343 contains important positive regulatory elements for efficient expression of NNMT promoter in BHP 2-7 cells. The sequence between Ϫ343 and ϩ1 is referred to as the NNMT basal promoter region. These results indicated that NNMT promoter might be regulated by different factors in the two different papillary cancer cell lines. In BHP 2-7 cells, strong NNMT promoter activity was dependent on upstream regulatory elements, whereas in BHP 14-9 cells, regulatory ele-ments in the basal promoter region alone were able to maintain relatively high promoter activity.
Differential Expression of HNF-1␤ in Thyroid Cancer Cells
NNMT is dominantly expressed in the human liver (3). The mechanism for this tissue-specific expression is unknown. Expression of liver-specific transcription factors in the papillary thyroid cancer cells may be responsible for the high level of NNMT expression. The HNF-1 transcription factors, HNF-1␣ and HNF-1␤, are expressed in liver and other tissues and are responsible for the expression of many tissue-specific genes (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) . Their expression in representative thyroid cancer cell lines and some nonthyroid cancer cell lines was determined by RT-PCR (Fig. 2) . The sizes of the expected PCR products are 234 and 317 bp for HNF-1␣ and HNF-1␤, respectively. HNF1-␤ expression was detected in papillary cancer cell lines, BHP 2-7, BHP 7-13, BHP 10-3, BHP 18-21, and TPC 1, liver cancer cell line Hep G2, and prostate cancer cell line LNCaP. The levels of HNF-1␤ mRNA in these papillary cancer cells were significantly higher than that in the Hep G2 cells. HNF-1␤ expression was not detected in papillary cancer cell lines BHP 5-16, BHP 14-9, BHP 15-3, and NPA 87, follicular cancer cell lines WRO 82-1, FTC 133, FTC 238, ML-1A, and ML-1B, Hurthle cancer cell line XTC-1, breast cancer cell line MCF-7, and primary thyroid cell cultures, O4 (goiter) and HX5 (normal). HNF-1␣ mRNA was detected strongly in Hep G2 cells and very weakly in the papillary cancer cell line NPA 87 but not in any RT-PCR analysis for HNF-1␤, HNF-1␣, and GAPDH was performed with total RNA as described in other cell lines described above. The mRNA level of HNF-1␤ and HNF-1␣ in Hep G2 cells detected in this study is consistent with the results of a previous study that showed that the transcript level of HNF-1␤ was 10-20 times lower than that of HNF-1␣ (27) .
The presence of HNF-1␤ protein was analyzed by Western blot with nuclear extracts isolated from representative thyroid cancer cell lines (BHP 2-7 and BHP 18-21, HNF-1␤ positive; BHP 14-9 and WRO 81-1, HNF-1␤ negative) and liver cancer cell line Hep G2 with HNF-1␤ specific antibody. As expected, HNF-1␤ protein with an expected molecular mass of 61.3 kDa was detected in the nuclear extracts of BHP 2-7, BHP 18-21, and Hep G2 cells and was not detected in the nuclear extracts of BHP 14-9 and WRO 81-1 (Fig. 3) . Consistent with RT-PCR analysis (Fig. 2) , the level of HNF-1␤ protein in BHP 2-7 and BHP 18-21 cells was much higher than that in Hep G2 cells.
The expression profiles of HNF-1␣, HNF-1␤, and NNMT in the cell lines tested above are summarized in Table 1 . It was found that NNMT gene expression correlated with HNF-1␤ gene expression. All papillary thyroid cancer cell lines with high levels of NNMT are HNF-1␤ positive, whereas other papillary cancer cell lines, follicular cancer cell lines, and primary normal thyroid cell cultures that are NNMT negative or have relatively lower NNMT gene expression are HNF-1␤ negative. These findings suggested that HNF-1␤ may be a positive regulator of the NNMT gene in the papillary cancer cells with higher NNMT expression.
NNMT Expression in Nonthyroid Cancer Cells
The three nonthyroid cancer cell lines, Hep G2 (liver cancer), MCF-7 (breast cancer), and LNCaP (prostate cancer), tested above showed different HNF-1␤ expression. To determine whether NNMT expression correlates with HNF-1␤ expression in these nonthyroid cancer cell lines, NNMT mRNA level was determined by RT-PCR. The results presented in Fig. 4 indicate that NNMT is expressed in the HNF-1␤-positive LNCaP cells, but not in the HNF-1␤-negative MCF-7 cells. These results suggested that HNF-␤ might also be required for NNMT expression in some nonthyroid cancer cells. NNMT expression in Hep G2 cells was not detected by RT-PCR under the conditions specified (Fig. 4) . We also tested NNMT, HNF-1␣, and HNF-1␤ expression in Hep G2 cells from a different source and found that the results (data not shown) were the same as those described in Figs. 2 and 4. To verify the results of RT-PCR analysis, we performed NNMT catalytic activity assay using cell extracts isolated from the Hep G2 cells. Cell extract isolated from BHP 18-21 cells was used as a positive control. Total RNA was subjected to RT-PCR analysis for NNMT and GAPDH as described in Materials and Methods. RNA isolated from BHP 2-7 cells was used as a positive control for NNMT.
Fig. 3. Detection of HNF-1␤ Protein in Thyroid Cancer Cells by Western Blot
Nuclear proteins (20 g) were separated on a 10% SDSpolyacrylamide gel. After being transferred to a nitrocellulose membrane, the membrane blot was probed with anti-HNF-1␤ antibodies. Cell lines: BHP 2-7 and BHP 18-21, papillary and HNF-1␤ positive; BHP 14-9 (papillary) and WRO 82-1 (follicular), HNF-1␤ negative; Hep G2, liver cancer. Strong NNMT catalytic activity was detected in BHP 18-21 cells as reported previously (2), whereas in Hep G2 cells very weak activity was detected (Table 2) . These results are consistent with those of the NNMT mRNA assay, suggesting that poor NNMT expression in the Hep G2 cells is limited at the transcription level.
Identification of a Functional HNF-1 Binding Site in the NNMT Promoter Region
To determine whether HNF-1␤ is directly involved in the regulation of NNMT gene expression, we first screened for HNF-1 binding sites in the cloned NNMT promoter region by DNA sequence analysis. A sequence located between nucleotide Ϫ148 and Ϫ162 relative to the NNMT translation initiation codon was identified with high homology to the HNF-1 consensus sequence (or idealized binding sequence) (40) (Fig. 5 ).
To test whether this putative HNF-1 site is functional, TTAA to CATT mutations were introduced into the site in the NNMT luciferase reporter plasmid pKM by sitedirected mutagenesis (Fig. 5) . The mutant plasmid, pKMmt, was tested to determine whether the mutation had any effects on NNMT promoter activity in three representative cancer cell lines, BHP 2-7, Hep G2, and BHP 14-9, by luciferase reporter gene assay.
In the HNF-1␤-positive BHP 2-7 cells, the HNF-1 binding site mutation decreased NNMT promoter activity about 5-fold (Fig. 5 ). In the Hep G2 cells, which express HNF-1␤ at a low level, the HNF-1 binding site mutation also decreased NNMT promoter activity significantly. The effect, however, was significantly smaller than that observed in the BHP 2-7 cells. This result suggested that the putative HNF-1 site is functional and is important for NNMT promoter activity in the HNF-1␤-positive BHP 2-7 cells. In contrast, the HNF-1 site mutation had no negative effects on NNMT promoter activity in the HNF-1␤-negative BHP 14-9 cells. This result was expected because HNF-1␤ was not expressed in this cell line.
Results presented in Figs. 1 and 5 indicated that NNMT promoter activity in the HNF-1␤-positive BHP 2-7 papillary cancer cells is strongly dependent on the HNF-1 site in the basal promoter region and regulatory elements in the upstream sequence. Mutation of the HNF-1 site or deletion of the upstream sequence dramatically decreased promoter activity. Because HNF-1 dependent transcription usually involves cooperation with other transcription factors (34, (41) (42) (43) , effects of the NNMT upstream sequence on HNF-1␤ function were examined. The NNMT basal promoter constructs with (pKM⌬1mt) or without (pKM⌬1) the HNF-1 site mutation were transfected into BHP 2-7, BHP 14-9, and Hep G2 cells and promoter activity was measured. The results were similar to those obtained with the constructs carrying the NNMT upstream sequence. In the presence of the HNF-1 site mutation, NNMT basal promoter activity was decreased up to 4-and 2-fold in the HNF-1␤-positive BHP 2-7 and HepG2 cells, respectively (Fig. 5) . These results suggested that HNF-1␤ was able to activate NNMT promoter efficiently in the absence of the upstream regulatory elements. However, possible cooperation between HNF-1␤ and a factor binding to the upstream sequence cannot be simply ruled out. In the HNF-1␤-negative BHP 14-9 cells, the mutation had no significant effects on promoter activity as expected, indicating that NNMT promoter activity in BHP 14-9 cells is independent of the HNF-1 site. Other unidentified regulatory elements in the basal promoter region may be important for the high NNMT basal promoter activity in BHP 14-9 cells.
Binding of HNF-1␤ to NNMT Basal Promoter Region
To demonstrate that the HNF-1␤ protein expressed in the papillary cancer cells binds directly to the HNF-1 site in the NNMT basal promoter region, nuclear extract isolated from BHP 2-7 cells was first tested for HNF-1␤ binding activity by gel retardation assay. The NNMT HNF-1 oligonucleotide was labeled with 32 P and used as a DNA probe. A major specific retardation complex was observed (Fig. 6A) . This complex could be competed out by 50-fold excess unlabeled NNMT HNF-1 oligonucleotide and consensus HNF-1 oligonucleotide, but not by the mutant NNMT HNF-1 oligonucleotide. Furthermore, the complex was supershifted by an HNF-1␤-specific antibody (Fig. 6B ) but did not react with an HNF-1␣-specific antibody (Fig.  6C) . Because HNF-1␣ is not expressed in the papillary cancer cells, this complex is assumed to be the homodimer form of HNF-1␤ (HNF-␤/␤).
To confirm the results described above, similar experiments were performed with nuclear extract isolated from Hep G2 cells, in which HNF-1␣ and HNF-1␤ expression is well documented. In contrast to that observed with BHP 2-7 nuclear extract, the major specific protein-DNA complex detected with the Hep G2 nuclear extract was the HNF-1␣ homodimer complex (HNF-1␣/␣) (Fig. 6, A, B, and C) . This complex migrates slower than the HNF-1␤/␤ complex. It could be competed out by 50-fold excess unlabeled NNMT HNF-1 oligonuclotide or consensus HNF-1 oligonucleotide, but not by the mutant NNMT HNF-1 oligonucleotide. It was supershifted by HNF-1␣-specific antibody, but not by the HNF-1␤-specific antibody. The HNF-1␤/␤ binding activity was very weak in the Hep G2 cells. Most of the HNF-1␤ protein expressed in this cell line was present as a heterodimer with HNF-1␣ (HNF-1␣/␤). The HNF-1␣/␤ complex is located between the HNF-1␣/␣ and HNF-1␤/␤ complexes. This complex was also sensitive to competition by the unlabeled NNMT HNF-1 oligonucleotide and the consensus HNF-1 oligonucleotide, but not the mutant NNMT HNF-1 oligonucleotide. The intensity of this complex was diminished when either HNF-1␤-or HNF-1␣-specific antibody was added to the binding reactions. The overall HNF-1␤ binding activity, including HNF-1␣/␤ and HNF-1␤/␤ in the Hep G2 cells, was much lower than that in the BHP 2-7 papillary cancer cells.
In addition to BHP 2-7, four additional thyroid cancer cell lines were also assayed for HNF-1␤ binding activity by gel retardation assay. BHP 2-7 and Hep G2 nuclear extracts were used as positive controls for HNF-1␤ and HNF-1␣, respectively. As expected, HNF-1␤ binding activity was also detected strongly in nuclear extracts isolated from the HNF-1␤-positive papillary cancer cells, BHP 18-21, and BHP 7-13 (Fig.  7 , lane 3 and 5) but not detected or detected only at very low level in the nuclear extracts of the HNF-1␤-negative cells: BHP 15-3 (papillary cancer), WRO 82-1 (follicular cancer), and MCF-7 (breast cancer). HNF-1␣/␣ or HNF-1␣/␤ binding activity was not detected in any of the cancer cells lines studied except Hep G2. These results are consistent with the assay for HNF-1␤ and HNF-1␣ expression determined by RT-PCR (Fig. 2 and Table 1 ).
Transient Expression of HNF-1␤ Enhanced NNMT Promoter Activity and Endogenous NNMT Protein Level
The results shown above suggested that HNF-1␤ activates NNMT promoter in the HNF-1␤-positive BHP 2-7 papillary cancer cells by binding to the HNF-1 site in the NNMT promoter region. To further confirm these results, the effect of transient HNF-1␤ expression on NNMT promoter activity was tested by cotransfection assay. HNF-1␤ cDNA was cloned into the mammalian gene expression vector pcDNA3.1(ϩ) as described in Materials and Methods. The HNF-1␤ expression plasmid was cotransfected with the NNMT luciferase reporter plasmid pKM (wild type) or pKMmt (HNF-1 binding site mutant) into Hep G2, BHP 2-7, BHP 14-9, or WRO 82-1 cells. In Hep G2 cells, expression of HNF-1␤ increased NNMT promoter activity significantly in a dose-dependent manner (Fig. 8A) . At the highest dose (250 ng/transfection), NNMT promoter activity was increased 2.2-fold. The effect of HNF-1␤ on NNMT promoter activity is direct because no activation was observed when the wild-type plasmid pKM was replaced by the HNF-1 site mutant plasmid, pKMmt. In fact, the HNF-1␤-independent promoter activity was inhibited slightly by the HNF-1␤ expression plasmid for unknown reasons. In BHP 2-7 and BHP 14-9 papillary cancer cells and WRO 82-1 follicular cancer cells, NNMT promoter activity of the wildtype reporter construct was increased about 3.5-, 2.5-, and 3-fold, respectively, by cotransfection with the HNF-1␤ expression plasmid (250 ng/per transfection). Promoter activity of the mutant construct (pKMmt), on the other hand, was inhibited slightly by HNF-1␤ overexpression as observed in Hep G2 cells (Fig. 8A) . These results further suggested that HNF-1␤ is able to function as a transcription activator of the NNMT promoter in these cells.
Similar experiments were also performed with the NNMT basal promoter constructs with BHP 2-7 and BHP 14-9 cells. Cotransfection of the HNF-1␤ expression plasmid with the wild-type construct, pKM⌬1, increased NNMT basal promoter activity about 8-fold in BHP 2-7 cells and 2.5-fold in BHP 14-9 cells (Fig.  8B) . Under the same conditions, the HNF-1␤ expression plasmid had no significant effects on promoter activity of the HNF-1 binding site mutant construct, pKM⌬1mt, in both cell lines. This result is consistent with the results presented in Fig. 5 and further suggests that the HNF-1␤ is able to activate NNMT promoter in the absence of the NNMT upstream sequence. Interestingly, the impact of HNF-1␤ on NNMT promoter activity is more notable in BHP 2-7 cells than in BHP 14-9 cells.
The effect of HNF-1␤ on endogenous NNMT expression was determined in BHP 14-9 cells that are HNF-1␤ negative and have lower NNMT expression ( Table 1 ). The cells were transfected with the HNF-1␤ expression plasmid, pcDNA3.1 vector, or NNMT expression plasmid. Nuclear extracts and cytoplasmic fractions were prepared 48 h after transfection and assayed for HNF-1␤ protein and NNMT protein, respectively, by Western blotting with HNF-1␤-and NNMT-specific antibodies. HNF-1␤ was detected in the cells transfected with the HNF-1␤ expression plasmid but not in the cells transfected with the cloning vector or NNMT expression plasmid (Fig. 9, upper panel) . Accompanying HNF-1␤ expression, the endogenous NNMT protein level in BHP 14-9 cells was significantly enhanced when it was compared with cells transfected with the vector only (Fig. 9,  lower panel) . In the cells transfected with the NNMT expression plasmid (positive control), NNMT protein level was also increased as expected. The apparent molecular mass of NNMT protein expressed in the thyroid cancer cells is similar to that identified in the liver cells (29 kDa) (3).
In summary, transient expression of HNF-1␤ enhanced NNMT promoter activity significantly in the HNF-1␤-positive BHP 2-7 and Hep G2 cells and HNF-1␤-negative BHP 14-9 and WRO 82-1 cells, and enhanced endogenous NNMT protein level in BHP 14-9 cells. These results suggest that HNF-1␤ functions as a transcription activator of NNMT gene in the papillary cancer cells with strong NNMT expression.
DISCUSSION
NNMT was expressed highly in many human papillary thyroid cancers and cell lines (2) . The mechanism leading to this overexpression was studied in representative papillary cancer cell lines. Several lines of evidence suggested that HNF-1␤ is directly involved in the activation of NNMT gene expression in the papillary cancer cells with strong NNMT expression. In these cells, the expression of HNF-1␤ gene was demonstrated by RT-PCR analysis (Fig. 2) , and HNF-1␤ protein and DNA binding activity were detected by Western blotting and gel retardation assay (Figs. 3, 6 , and 7). A putative HNF-1 binding site was identified in the cloned NNMT promoter region. HNF-1␤ bound to this site specifically as a homodimer. Mutations in this site abolished HNF-1␤ binding (Fig. 6 ) and decreased NNMT promoter activity significantly in the HNF-1␤-positive papillary cancer cells (BHP 2-7) but not promoter activity in the HNF-1␤-negative papillary cancer cells (BHP 14-9) (Fig. 5) . Overexpression of HNF-1␤ enhanced NNMT promoter activity of the wild-type reporter gene construct significantly in both HNF-1␤-positive and -negative cells but not promoter activity of the construct with the HNF-1 binding site mutation (Fig. 8) . In addition, transient expression of HNF-1␤ in BHP 14-9 cells enhanced the endogenous NNMT protein level (Fig. 9) . The combined results suggest that HNF-1␤ is able to function as a transcription activator of NNMT promoter and is at least partially responsible for the high level of NNMT gene expression in the HNF-1␤-positive papillary cancer cells.
In other papillary cancer cells, follicular cancer cells, and primary thyroid cultures that have relatively lower or no NNMT expression, HNF-1␤ mRNA was not detected by RT-PCR. HNF-1␤ protein or binding activity was not detected or detected only very weakly in representative HNF-1␤-negative cell lines. In addition, mutations in the HNF-1 site had no negative effects on promoter activity in BHP 14-9 cells. It is likely that the strong NNMT basal promoter activity in the HNF-1␤-negative BHP 14-9 cells is dependent on some other factors. Because transient expression of HNF-1␤ was able to enhance NNMT promoter activity specifically in BHP 14-9 papillary cancer cells and WRO 82-1 follicular cancer cells and endogenous NNMT protein level in the BHP 14-9 cells, the absence of HNF-1␤ may be partially responsible for the lower or poor NNMT gene expression in these cells.
The NNMT promoter construct carrying NNMT sequence from Ϫ2607 to ϩ1 showed differential expression in papillary cancer cell lines and follicular cancer cell lines. It expressed well in all the papillary cancer cell lines, including those with lower NNMT gene expression, but poorly in the follicular cancer cell lines (Fig. 1) . These results are consistent with our previous data showing that the NNMT gene was expressed poorly in many follicular cancers or cell lines (2) . The cloned NNMT promoter may contain essential elements for efficient expression in papillary cancer cells. The construct, however, was unable to reflect the difference in NNMT gene expression between papillary cancer cell lines with high level NNMT gene expression (e.g. BHP 2-7) and papillary cancer cell lines with relatively lower NNMT expression (e.g. BHP 14-9). Further study with a 5Ј-deletion construct in two representative papillary cancer cell lines, BHP 2-7 and BHP 14-9, suggested that NMT promoter might be regulated differently in the two cell lines. In the BHP 2-7 cells, strong NNMT promoter activity was dependent on upstream regulatory elements and a HNF-1 site in the basal promoter region. Deletion of the upstream sequence or mutation of the HNF-1 site dramatically reduced NNMT promoter activity. In BHP 14-9 cells, the basal promoter region alone was able to maintain relatively high promoter activity, and the HNF-1 site was not functional because of the absence of HNF-1␤ expression in this cell line. The upstream sequence was required for full promoter activity in the BHP 14-9 cells, but was not as important as it was in the BHP 2-7 cells. In addition, we found that the NNMT basal promoter contained in the 5Ј-deletion construct, pKM⌬1, responded strongly to glucocorticoid (dexamethasone) in BHP 2-7 cells, but insignificantly in BHP 14-9 cells (Xu, J., and J. M. Hershman, unpublished data), further suggesting that different factors are involved in the regulation of NNMT promoter in the two different cell lines. Because papillary cancers can be caused by different mutations, such as RET and NTRK1 rearrangements and BRAF mutations, the regulation of NNMT by different mechanisms in different papillary cancer cells is possible. By DNA microarray analysis, Frattini et al. (44) reported that papillary thyroid cancers with RET and NTRK1 rearrangements and BRAF mutations had similar but distinct gene expression patterns. We have noticed that the papillary cancer cell lines with high NNMT expression (such as BHP 2-7 and BHP 18-21) are RET/PTC1 rearrangement positive and the papillary cancer cell lines with lower NNMT expression (such as BHP 5-16, BHP 14-9, BHP 15-3, and NPA 87) are RET/PTC1 negative (2). NPA 87 was reported to carry a BRAF mutation (45) . The mutations leading to papillary cancer in BHP 5-16, BHP 14-9, and BHP 15-3 cells are unclear. Further work is needed to fully understand the difference in NNMT gene regulation between the two subsets of papillary cancer cell lines. It is possible that additional regulatory elements outside of the cloned NNMT promoter region between Ϫ2607 and ϩ1 may be required to mimic endogenous NNMT gene expression in the two subsets of papillary cancer cell lines. These elements may provide additional activation of the NNMT promoter in the cells with high NNMT gene expression (e.g. BHP 2-7) or repression of NNMT promoter in the cells with relatively lower NNMT expression (e.g. BHP 14-9). Other factors, such as RNA stability and posttranscriptional regulation, may also affect the steady-state NNMT mRNA level or protein level. All these issues remain to be clarified. The relationship between HNF-1␤ and NNMT expression in the Hep G2 liver cancer cells is complex. We showed that NNMT is not expressed or poorly expressed in this cell line as determined by RT-PCR and catalytic activity assay. HNF-1␤ gene expression in Hep G2 cells, as determined by RT-PCR, Western blotting, and gel retardation assay, was much lower than that in the papillary cancer cells that expressed NNMT at high level. The HNF-1␤ binding activity in Hep G2 cells was mainly detected as a heterodimer (HNF-1␣/␤) with HNF-1␣, which was expressed at a much higher level than HNF-1␤. The HNF-1␤/␤ binding activity was barely detected. As the HNF-1␤/␤ form is highly functional in the papillary cancer cells, the absence of NNMT expression in Hep G2 may be due to insufficiency of the functional HNF-1␤/␤ forms. HNF-1␣ protein is structurally and functionally related to HNF-1␤. It can activate some HNF-1␤-dependent promoters (29, 31) . A relatively highly expressed HNF-1␣ in the Hep G2 cells seems to be unable to compensate for lack of HNF-1␤ in the activation of the NNMT gene, assuming that HNF-1␤ is important for NNMT expression in the liver cells. Further study is needed to determine the role of HNF-1␣ in NNMT gene expression in the liver cells. The human ␣ 1 -antitrypsin gene was activated by HNF-1␤ in a cell-dependent manner. It was activated in the human pulmonary epithelial cell line H441 by HNF-1␤, but not in Hep G2 cells (31) . This is a situation very similar to the NNMT expression described in this study, implying that other cell-specific factors may be involved in the HNF-1␤ dependent activation of NNMT gene. The hypothesis for the requirement of other factors is consistent with the facts that mutations in the HNF-1 site in the NNMT promoter and transient expression of HNF-1␤ had significantly less impact on NNMT promoter activity in Hep G2 cells than in BHP 2-7 papillary cancer cells. These other factors may function cooperatively with HNF-1␤ as reported in other systems (34, (41) (42) (43) . Alternatively, they may function in an HNF-1␤-independent manner. We have found that the NNMT upstream sequence is very important for NNMT promoter activity in BHP 2-7 cells, whereas deletion of this sequence had no major effects on the activation of NNMT promoter by HNF-1␤ (Figs. 5 and 8) . It is possible that some factors binding to the upstream regulatory elements may function independently of HNF-1␤.
HNF-1␤ is a transcription factor normally expressed in tissues such as liver, pancreas, lung, kidney, and intestine. To our knowledge, the expression of HNF-1␤ in thyroid cells has not been reported previously. By study of NNMT gene expression, we showed that HNF-1␤ is overexpressed in many papillary thyroid cancer cell lines. As HNF-1␤ is a transcription factor involved in the expression of genes involved in many different cellular functions, the possible pathological function of HNF-1␤ in some papillary thyroid cancers will be a very interesting issue to investigate. It was shown recently that inhibition of HNF-1␤ expression caused apoptosis in ovarian clear cancer cells (25) .
Our future study will focus on the detection of HNF-1␤ expression in thyroid cancer specimens and potential implications of HNF-1␤ expression on the behavior of the HNF-1␤-positive thyroid cancers.
MATERIALS AND METHODS
Cell Culture
Human papillary thyroid cancer cell lines, BHP 2-7, BHP 18-21, BHP 7-13, BHP 10-3, BHP5-16, BHP 14-9, and BHP 15-3, were established previously in our laboratory (46 Louis, MO) supplemented with 2 g/liter sodium bicarbonate, 0.14 mM nonessential amino acids, 1.4 mM sodium pyruvate, and 10% fetal bovine serum, pH 7.2). ML-1A and ML-1B cells were grown in the M199 medium [M199 medium base (Sigma) supplemented with 2.2 g/liter sodium bicarbonate, 10% fetal bovine serum, and 1ϫ PSN antibiotic mixture (Life Technologies, Gaithersburg, MD)]. Human hepatocellular carcinoma cell line Hep G2 (ATCC, Manassas, VA) was grown in Eagle's MEM (Sigma) supplemented with 1.5 g/liter sodium bicarbonate, 0.1 mM nonessential amino acids, 1 mM sodium pyruvate, and 10% fetal bovine serum.
Plasmid Construction
To clone the NNMT promoter region, genomic DNA isolated from papillary thyroid cancer cell line BHP 18-21 was used as template to amplify NNMT promoter sequence using the Expand High Fidelity PCR System (Roche Clinical Laboratories, Indianapolis, IN). Primers used for PCR amplification were designed based on the NNMT genomic DNA sequences in GenBank (National Center for Biotechnology Information, Bethesda, MD). DNA sequences of the primers are: forward, 5Ј-ACGGTACCTATTCAGTCATAAAGAAGAATTAGATCCTG-3Ј; reverse, 5Ј-TAACGCGTTATGTCTCACTTCTGTACCACT-GGA-3Ј. The sequences underlined at the 5Ј-ends of the primers were added to create a unique KpnI site at the 5Ј-end and a unique MluI site at the 3Ј-end of the PCR fragment. After restriction digestion with KpnI and MluI, the 2.6-kb NNMT promoter DNA from Ϫ2607 to ϩ1 relative to the translation initiation codon was cloned into corresponding sites in the firefly luciferase reporter gene vector pGL3-basic (Promega Corp., Madison, WI) to generate NNMT-luciferase reporter plasmid pKM. Plasmid pKM⌬1 was constructed by deletion of NNMT upstream sequence between Ϫ2607 and Ϫ343 from pKM. Plasmid pKMmt is a derivative of pKM with mutations in the HNF-1 binding site in the NNMT basal promoter region. The mutations were introduced by a twostep RT-PCR protocol with a mutagenic oligonucleotide (5Ј-GGTCTATTTCTCTGTTAGTGTCATTCCAACCATCTGTTCT-AA-3Ј, nucleotide substitutions underlined) and Pfu DNA polymerase (Stratagene, La Jolla, CA). pKM⌬1mt was identical to pKM⌬1 except for mutations in the HNF-1 site.
A HNF-1␤ expression plasmid was constructed as follows. Total RNA isolated from BHP 2-7 cells was reverse transcribed. The reverse transcription products were PCR ampli-fied using Pfu polymerase and HNF-1␤ specific primers. The sequences of the primers are: forward, 5Ј-TTGGATCCTTC-CGTCCTTGGAAAATGGTGT-3Ј; reverse, 5Ј-GCTCTAGAAG-TAAGTGGTGTGTGGGCATCA-3Ј. The sequences underlined were added to generate unique BamHI and XbaI restriction sites at the 5Ј-and 3Ј-ends of the cDNA fragment. The HNF-1␤ cDNA was cloned into a mammalian expression vector, pcDNA3.1(ϩ), after being restriction digested with BamHI and XbaI. Similar procedures were also used to construct the NNMT expression plasmid. The sequences of the primers used to clone NNMT cDNA are: forward, 5Ј-GCGC-TAGCCTGAGACTCAGGAAGACAACTTCT-3Ј; reverse, 5Ј-T-TGGATCCAGGTCAAAGGAATTGCTTTAATTGAG-3Ј. Unique NheI and BamHI restriction sites (underlined) were added to the forward and reverse primers, respectively. The NNMT cDNA was cloned into corresponding restriction sites in pcDNA3.1(Ϫ). The expression of both HNF-1␤ and NNMT cDNAs was under the control of the cytomegalovirus (CMV) promoter. All plasmid constructs were confirmed by DNA sequencing.
Transfection and Reporter Gene Assay
For transient transfection, about 2 ϫ 10 5 cells were seeded onto each well of a 12-well plate. After growing about 24 h, the cells were transfected with 0.5 g of firefly luciferase reporter gene plasmid and 25 ng of Renilla luciferase control reporter gene plasmid pRL-CMV (Promega) with Effectene (QIAGEN, Inc., Valencia, CA). About 18 h after transfection, Effectene-DNA and medium mixture were removed. The transfected cells were grown in fresh growth medium for 28 h. Luciferase activities were then assayed using the dual-luciferase assay kit (Promega). The firefly reporter gene activities were normalized with the control reporter gene activities. Experiments were performed two to three times and data represent mean Ϯ SD.
Semiquantitative RT-PCR
Total RNA was isolated from cultured cells using the RNeasy Mini Kit (QIAGEN). Total RNA (1 g) was reverse transcribed in a total volume of 10 l for 90 min at 37 C with the Omniscript RT Kit (QIAGEN) using oligo (dT11-13) primers (Life Technologies). The reverse transcription product (1 l) was subjected to PCR in a total of 50 l with Taq polymerase. The PCR conditions were: NNMT, 94 C for 30 sec, 56.7 C for 30 sec, 72 C for 30 sec, 26 cycles; HNF-1␣, 94 C for 30 sec, 60 C for 30 sec, 72 C for 40 sec, 33 cycles; HNF-1␤, 94 C for 30 sec, 63 C for 30 sec, 72 C for 50 sec, 35 cycles; glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 94 C for 30 sec, 57 C for 30 sec, 72 C for 40 sec, 21 cycles. The sequences of the gene-specific primers were: NNMT, 5Ј-GTT-TGGTTCTAGGCACTCTGCA-3Ј (forward)/5Ј-GCAGAGAGG-AGCTGATAGATAGTGG-3Ј (reverse); HNF-1␣, 5Ј-AGACAC-TGAGGCCTCCAGTGAGT-3Ј (forward)/5Ј-GAGATGAAGGT-CTCGATGACGCT-3Ј (reverse); HNF-1␤, 5Ј-AGCTGTCAGG-AGTGCGCTACAGC-3 (forward)/5Ј-GGAGGTGTTGAGGCT-TTGTGCA-3Ј (reverse); GAPDH, 5Ј-GCTGCCAAGGCTGTG-GGCAAGGTC-3Ј (forward)/5Ј-TTGTCATACCAGGAAATGA-GCTT-3Ј (reverse). PCR products were separated by agarose gel electrophoresis.
Nuclear Extract Isolation and Gel Retardation Assay
Nuclear extracts were isolated according to the method described previously (47) . Double-stranded oligonucleotides carrying a NNMT HNF-1 binding site were end labeled with [␥-32 P]ATP by polynucleotide kinase. The labeled oligonucleotides were purified with the QIAGEN nucleotide removing kit (QIAGEN) and then used as DNA probe for gel retardation assays. Nuclear extracts (10 g) were first incubated with 2 g of nonspecific DNA competitors [poly (DI-dC).(dI-dC)] in a binding buffer [20 mM HEPES, pH 7.8; 5% glycerol, 50 mM KCl; 1 mM EDTA; 1 mM dithiothreitol] for 10 min at room temperature. Specific DNA competitor (when it was used) was added in 50 molar excess to the binding buffer before nuclear extracts were added. About 10 fmol of the DNA probe were added to the binding mixture, and the binding reaction was performed at room temperature for 30 min. Antibodies for HNF-1␣ (C-19) and HNF-1␤ (C-20) were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Antibodies were added 2 g per reaction 10 min after addition of the DNA probe. The final volume of the binding reaction was 15 l. DNA-protein complexes were separated by electrophoresis in a 5% polyacrylamide gel in half-strength Tris-borate-EDTA buffer. Radioactive bands were detected by autoradiography. The DNA sequences of the oligonucleotides used as DNA probe or competitors are (top strand only): NNMT HNF-1 binding site, 5Ј-TATTTCTCTGTTAGTGTTTAACCAA-CCATCT-3Ј; NNMT HNF-1 binding site mutant, 5Ј-TATTTC-TCTGTTAGTGTCATTCCAACCATCT-3Ј, mutations underlined; consensus HNF-1 binding site, 5Ј-TCGATGTGGTTAATGATTA-ACCGTT-3Ј (40) .
NNMT Catalytic Activity Assay
NNMT catalytic activity assay for cultured cells was performed as described previously (2, 3) . Radioactive S-[methyl-14 C]adenosyl-1-methionine (SA, 53 mCi/mmol; ICN Biochemicals, Inc., Costa Mesa, CA) was used as the methyl donor and nicotinamide as the methyl acceptor. Radioactivity of the reaction product, N 1 -[ 14 C]methylnicotinamide, was measured with a liquid scintillation counter (LS6000 SC, Beckman Instruments, Inc., Fullerton, CA) after being separated from the substrates by extraction with isoamyl alcohol/ toluene. NNMT activity was expressed as counts per min (cpm) per g protein.
Western Blotting
Proteins were electrophoresed on sodium dodecyl sulfate (SDS)-polyacrylamide gel and transferred to nitrocellulose membranes. The membrane blots were incubated with rabbit polyclonal antibody (1:1000 dilution) against human HNF-1␤ (H-85; Santa Cruz Biotechnology) or NNMT (Dr. Richard Weinshilboum, Mayo Clinic, Rochester, MN) for 3 h followed by incubation with horseradish peroxidase-conjugated goat antirabbit IgG (Pierce Chemical Co., Rockford, IL; 1:2000 dilution) for 1.5 h. HNF-1␤ and NNMT proteins were visualized using an enhanced chemiluminescent substrate (SuperSignal West Femto Maximum Sensitivity Substrate, Pierce).
Statistical Analysis
Statistical analysis was performed with Student's t test with significance at P Ͻ 0.05.
